Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOST | Q9BQB4 | 1/20 | 0.75 |
| ▸ | FPGS | Q05932 | 2/20 | 0.74 |
| ▸ | GART | P22102 | 4/20 | 0.56 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MTHFD1 | P11586 | 1/20 | 0.49 |
| ▸ | ATIC | P31939 | 4/20 | 0.49 |
| ▸ | NOS1 | P29475 | 2/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7077904 | 0.94 | SOST (0.85) | SOSTFPGSGARTDHFRLMNA | |
| SCHEMBL133543 | 0.94 | SOST (0.85) | SOSTFPGSGARTDHFRLMNA | |
| SCHEMBL20509041 | 0.94 | SOST (0.85) | SOSTFPGSGARTDHFRLMNA | |
| SCHEMBL10464162 | 0.94 | SOST (0.85) | SOSTFPGSGARTDHFRLMNA | |
| SCHEMBL7076983 | 0.94 | SOST (0.85) | SOSTFPGSGARTDHFRLMNA | |
| SCHEMBL27903149 | 0.94 | SOST (0.85) | SOSTFPGSGARTDHFRLMNA | |
| SCHEMBL28206347 | 0.93 | SOST (0.84) | SOSTFPGSGARTDHFRLMNA | |
| SCHEMBL27284124 | 0.93 | SOST (0.84) | SOSTFPGSGARTDHFRLMNA | |
| SCHEMBL4613239 | 0.93 | SOST (0.67) | SOSTFPGSGARTDHFRLMNA | |
| Phosphoric Acid SCHEMBL28313723 | 0.92 | SOST (0.82) | SOSTFPGSGARTDHFRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816525-B1 | Process for the preparation of optically pure tetrahydropterins and derivatives, and specifically of optically pure tetrahydrofolic acid and derivatives thereof, by stereospecific hydrogenation | Merck & Cie (CH) | 2010-10-19 | — | — | US | disclosed |
| US-20080306263-A1 | Process For The Preparation Of Optically Pure Tetrahydropterins And Derivatives, And Specifically Of Optically Pure Tetrahydrofolic Acid And Derivatives Thereof, By Stereospecific Hydrogenation | MULLER HANS RUDOLF | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306263-A1 | Process For The Preparation Of Optically Pure Tetrahydropterins And Derivatives, And Specifically Of Optically Pure Tetrahydrofolic Acid And Derivatives Thereof, By Stereospecific Hydrogenation | DHFR, MTHFD2, MTHFD1 | SOST 2497/4885FPGS 12/4885GART 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.